This initiative is part of ARIA’s Safeguarded AI programme. The project, known as ‘Transforming clinical trial design using safe and reliable AI,’ will be a collaborative effort between Lindus Health ...

Under this agreement, NetraMark's AI technology will initially be used for Phase 2 (neuroscience and oncology clinical trials) and select Phase 3 clinical trials conducted by Worldwide ...

hThe Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA iDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone ...